You should mention that this graph is not from academics testing nootropics on a random sample, but self-reported from nootropics users. So it is non-random, uncontrolled, and unblinded.
The survey also had probabilities of side effects. Maybe include those? A cost-benefit analysis really should also include the potential costs, and not just the potential benefits.
You should mention that this graph is not from academics testing nootropics on a random sample, but self-reported from nootropics users. So it is non-random, uncontrolled, and unblinded.
The survey also had probabilities of side effects. Maybe include those? A cost-benefit analysis really should also include the potential costs, and not just the potential benefits.